A new analysis presented at the 2026 American Academy of Orthopaedic Surgeons (AAOS) Annual Meeting suggests that people with type 2 diabetes + obesity who used GLP-1 receptor agonists had a slightly higher 5-year risk of diagnoses like osteoporosis (and also gout) compared with matched non-users.
At Sōlaria Biō, we don’t read this as a reason to panic or a reason to ignore it. We read it as a familiar pattern: when weight changes fast, the skeleton notices.
And when appetite drops, nutrition, strength training, and monitoring become part of the actual treatment plan.
What the AAOS Analysis on GLP-1 Users vs. Non-Users Found
Researchers reviewed ~5 years of records from 146,000+ adults diagnosed with obesity and type 2 diabetes and compared GLP-1 users vs non-users. They reported higher rates of:
- Osteoporosis: ~4% vs a little over 3% (reported as ~30% relative increase)
- Gout: 7.4% vs 6.6% (reported as ~12% relative increase)
- Osteomalacia: rare, but more frequent among GLP-1 users
Importantly, this work was presented as a conference study and has not yet been published as a peer-reviewed paper.
Why GLP-1–Associated Weight Loss Could Affect Bone
1) Mechanical Unloading
Bone is living tissue that adapts to load. When body weight drops, especially quickly, bones may receive less mechanical stimulus. That can shift remodeling toward loss at key sites like the hip.
2) Nutrient Intake Can Quietly Fall
Appetite suppression is a feature, not a mistake. But lower food intake can mean lower protein, fiber, calcium, and vitamin D—all relevant to maintaining bone and muscle.
3) Muscle Loss Changes the Equation
Rapid weight loss can include lean mass loss. Less muscle can mean less force on bone (bad for density) and higher fall risk (bad for fractures).
This “weight loss → bone loss” pattern isn’t theoretical—it shows up in controlled trials. For example:
- In a randomized trial after diet-induced weight loss, liraglutide alone reduced hip and spine BMD, while exercise + liraglutide preserved bone health better.
- In adults at increased fracture risk, once-weekly semaglutide increased bone resorption markers and was associated with modest BMD reductions, plausibly related to accompanying weight loss.
Translation: the skeleton responds to the whole package (weight change, nutrient intake, and activity level) not just the prescription name.
Who Should Pay Extra Attention Right Now
If you’re using (or considering) a GLP-1, bone health deserves consideration if you have any of these:
- Perimenopause or postmenopause
- History of fracture, family history of osteoporosis
- Known osteopenia/osteoporosis, or you haven’t been screened and have risk factors
- Low protein intake, low vitamin D, or low activity
- Use of medications that can affect bone (your clinician will know the list)
This is especially relevant because bone loss is often silent until the first fracture occurs.
A Bone-Aware Approach to GLP-1 Care
We agree with the clinicians quoted in coverage of the AAOS findings: the takeaway isn’t fear, it’s a reminder to support the whole body during weight loss, including bones and joints.
Here are a few practical, low-friction ways to bring bone health into the conversation:
-
Ask about your baseline bone status
If you’re in midlife or have risk factors, it may be worth asking your clinician whether a DEXA (bone density) scan makes sense now, or whether it’s something to plan for down the road. -
Include strength training (as you’re able)
Some research suggests that pairing GLP-1 therapy with structured exercise, especially resistance training, may help reduce bone density loss during weight loss. If you’re not currently active, even starting small and building gradually can help. -
Keep an eye on protein and key nutrients
Because appetite can drop on GLP-1s, it can be easier than people expect to fall short on protein, fiber, and nutrients important for bone health (like calcium and vitamin D). Your clinician or dietitian can help you find an approach that fits your preferences and tolerances. -
Recheck over time, if you’re higher risk
For people with elevated fracture risk (or rapid weight loss), clinicians may recommend periodic follow-up—whether that’s repeating bone density testing or using other tools—based on your individual risk.
The Bottom Line
This AAOS signal is not a verdict. It’s a warning light, and a useful one.
GLP-1s can offer real metabolic upside. But if weight loss is part of the mechanism, bone and connective tissue need to be part of the conversation from day one, not year five.
Because the real goal isn’t just losing weight. It’s preserving strength, mobility, and independence while you do.
At Sōlaria Biō, we focus on what gets overlooked: early, proactive bone support, especially for the massive group of people living in the “not osteoporosis yet” zone where risk is already rising.
One reason we made Bōndia is that the standard advice (calcium, vitamin D, “exercise more”) is often incomplete, especially when biology is shifting (menopause, metabolic change, or weight loss). Bōndia is a plant-sourced synbiotic designed to support bone health through the gut–bone axis, with gold-standard clinical evaluation in menopausal women showing meaningful slowing of bone loss in higher-risk subgroups.
Educational only; not medical advice. If you’re on a GLP-1 (or considering one), talk with your healthcare professional about your individual fracture risk, nutrition, exercise plan, and whether bone density screening makes sense for you.
